Status:
TERMINATED
Glucose Homeostasis in Pseudohypoparathyroidism
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism
Pseudohypoparathyroidism Type Ia
Eligibility:
All Genders
6-50 years
Brief Summary
It is increasingly recognized that Pseudohypoparathyroidism type 1A (PHP1A) is associated with an increased risk of type 2 diabetes but the mechanism is unknown. In this pilot study we will assess β-c...
Detailed Description
Pseudohypoparathyroidism type 1A (PHP1A) is a rare, genetic disorder caused by impaired stimulatory G-protein signaling due to heterozygous mutations in the gene, GNAS. The most severe form of the dis...
Eligibility Criteria
Inclusion
- Diagnosis of PHP1A/PPHP
- Age between 6 and 50 years old
- Controls will be matched based on:
- Gender
- Race
- Age (±2 years if \<25 years old or ±5 years if ≥25 years old)
- BMI (±2 kg/m2)
- Diabetes status
Exclusion
- Treatment with appetite-altering drug or initiation of a new weight loss program in the past 3 months
- Type 1 diabetes
- Type 2 diabetes treated with insulin or GLP-1 receptor agonists or A1c \>9%at their most recent clinic visit
- Pregnant or lactating women
Key Trial Info
Start Date :
June 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03761290
Start Date
June 19 2019
End Date
April 30 2021
Last Update
May 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212